此页面是自动翻译的，不保证翻译的准确性。请参阅英文版对于源文本。

Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer

2020年10月21日更新者：Radiation Therapy Oncology Group

Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have stage II or stage III oropharyngeal cancer.

研究概览

地位

完全的

条件

干预/治疗

详细说明

OBJECTIVES:

Assess target coverage and major salivary gland sparing in patients with stage II or III oropharyngeal cancer treated with intensity-modulated radiotherapy.
Determine the nature and prevalence of acute and late side effects of this treatment in these patients.
Determine the rate and pattern of locoregional tumor recurrence in these patients after this treatment.

OUTLINE: This is a multicenter study.

Patients receive 3-D conformal radiotherapy and/or intensity-modulated radiotherapy daily 5 days a week for 6 weeks, in an effort to spare major salivary glands.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 57-64 patients will be accrued for this study over 27 months.

研究类型

介入性

阶段

阶段2
阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

加拿大
- Alberta
  - Edmonton、Alberta、加拿大、T6G 2R7
    - Stollery Children's Hospital at University of Alberta Hospital
- Quebec
  - Montreal、Quebec、加拿大、H2W 1S6
    - McGill Cancer Centre at McGill University
  - Montreal、Quebec、加拿大、H2L 4MI
    - Centre Hospitalier de l'Universite de Montreal
美国
- Arizona
  - Phoenix、Arizona、美国、85013
    - Foundation for Cancer Research and Education
- California
  - San Francisco、California、美国、94115
    - UCSF Comprehensive Cancer Center
- Florida
  - Gainesville、Florida、美国、32610-0385
    - University of Florida Shands Cancer Center
- Michigan
  - Ann Arbor、Michigan、美国、48109-0010
    - University of Michigan Comprehensive Cancer Center
- Missouri
  - Kansas City、Missouri、美国、64131
    - CCOP - Kansas City
- New Jersey
  - Long Branch、New Jersey、美国、07740-6395
    - Monmouth Medical Center
  - Toms River、New Jersey、美国、08755
    - Community Regional Cancer Center at Community Medical Center
- Pennsylvania
  - Philadelphia、Pennsylvania、美国、19107-5541
    - Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
- Texas
  - Houston、Texas、美国、77030-4009
    - M.D. Anderson Cancer Center at University of Texas
- Utah
  - Saint George、Utah、美国、84770
    - Dixie Regional Medical Center
  - Salt Lake City、Utah、美国、84143
    - LDS Hospital
- Vermont
  - Rutland、Vermont、美国、05701
    - Community Cancer Center at Rutland Regional Medical Center
- Wisconsin
  - Marshfield、Wisconsin、美国、54449
    - CCOP - Marshfield Clinic Research Foundation
  - Milwaukee、Wisconsin、美国、53226
    - Medical College of Wisconsin Cancer Center
  - Racine、Wisconsin、美国、53405
    - All Saints Cancer Center at All Saints Healthcare

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年至 120年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

DISEASE CHARACTERISTICS:

Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate)
- Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy
- Patients upstaged by imaging to N2 are eligible
Measurable or evaluable disease
- Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan
Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies
No distant metastases

PATIENT CHARACTERISTICS:

Age:

Over 18

Performance status:

Zubrod 0-1

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No active untreated infection
No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin
No concurrent major medical or psychiatric illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

More than 3 months since prior chemotherapy
No concurrent chemotherapy

Endocrine therapy:

Not specified

Radiotherapy:

No prior head or neck radiotherapy

Surgery:

See Disease Characteristics

Other:

No other concurrent treatment for head and neck cancer
No prophylactic amifostine or pilocarpine

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

主要用途：治疗

研究衡量的是什么？

主要结果指标

结果测量
Acute salivary gland toxicity
Locoregional control
Whole mouth saliva output relative to pre-radiotherapy measurements
Acute mucositis and other acute and late toxicities

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Radiation Therapy Oncology Group

合作者

National Cancer Institute (NCI)

调查人员

学习椅：Avraham Eisbruch, MD、University of Michigan Rogel Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

Ploquin N, Lau H, Dunscombe P. Intensity modulated and three-dimensional conformal radiation therapy plans for oropharyngeal cancer: a comparison of their sensitivity to set-up errors and uncertainties. Curr Oncol. 2006 Apr;13(2):61-6.
Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8. doi: 10.1016/j.ijrobp.2009.04.011. Epub 2009 Jun 18.
Eisbruch A, Harris J, Garden A, et al.: Phase II multi-institutional study of IMRT for oropharyngeal cancer (RTOG 00-22): early results. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-79, S46-7, 2006.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2001年2月1日

初级完成 (实际的)

2005年11月1日

研究完成 (实际的)

2016年12月1日

研究注册日期

首次提交

2000年10月4日

首先提交符合 QC 标准的

2003年1月26日

首次发布 (估计)

2003年1月27日

研究记录更新

最后更新发布 (实际的)

2020年10月22日

上次提交的符合 QC 标准的更新

2020年10月21日

最后验证